Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,271
Employees1,271
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,271
Employees1,271

INSM Key Statistics

Market cap
34.20B
Market cap34.20B
Price-Earnings ratio
-24.45
Price-Earnings ratio-24.45
Dividend yield
Dividend yield
Average volume
2.09M
Average volume2.09M
High today
$163.14
High today$163.14
Low today
$146.57
Low today$146.57
Open price
$153.78
Open price$153.78
Volume
3.85M
Volume3.85M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$60.40
52 Week low$60.40

Stock Snapshot

As of today, Insmed Incorporated(INSM) shares are valued at $157.88. The company's market cap stands at 34.2B, with a P/E ratio of -24.45.

On 2026-02-19, Insmed Incorporated(INSM) stock moved within a range of $146.57 to $163.14. With shares now at $157.88, the stock is trading +7.7% above its intraday low and -3.2% below the session's peak.

Trading activity shows a volume of 3.85M, compared to an average daily volume of 2.09M.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

INSM News

TipRanks 2h
Insmed price target lowered to $205 from $212 at Stifel

Stifel lowered the firm’s price target on Insmed (INSM) to $205 from $212 and keeps a Buy rating on the shares. Management’s provision of $1B-plus FY26 Brinsupr...

TipRanks 8h
Insmed director McGirr to step down after 2026 meeting

Insmed ( (INSM) ) has provided an update. On February 17, 2026, director David W.J. McGirr informed Insmed’s board that he will not stand for re-election at th...

TipRanks 8h
Insmed reports Q4 EPS ($1.54), consensus ($1.17)

Reports Q4 revenue $263.8M, consensus $263.98M. “As we close out 2025 and begin an exciting new year at Insmed (INSM), I am energized by the significant opportu...

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

More INSM News

Nasdaq 3d
What to Expect From These Drug/Biotech Players This Earnings Season?

The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a handful of pharma and biotech companies scheduled to r...

What to Expect From These Drug/Biotech Players This Earnings Season?

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.